The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Which strategies hold promise for treating TP53-mutated MDS?
In this video, David Sallman, MD, Moffitt Cancer Center, Tampa, FL, discusses the path forward for treating TP53-mutated patients with myelodysplastic syndromes (MDS), emphasizing the unmet need for TP53-specific strategies. Dr Sallman mentions the potential of several agents, including small-molecule reactivators like rezatapopt and novel immune therapies such as bexmarilimab. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
